Management Team

Arestat™ Protein Stabilization Technology

Arestat™ comprises two fundamentally different aspects of our platform stabilization technology. Both utilize excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability.

Both platform technologies are available for licensing for applications involving therapeutic proteins, vaccines, medical devices and diagnostics.

Management Team

Thomas Reese Saylor, CEO

Tom Saylor has extensive experience in pharmaceutical development, manufacturing and marketing. He

was CEO of Sirus, a drug targeting and delivery company, based in Cambridge, England
has been Chairman and founder of Lotus Healthcare Corporation, an Asian-based integrated pharmaceutical company producing and marketing analgesics, cardiovascular and gastrointestinal products
was CEO of Cell Systems Limited, a medical applications company in cryopreservation and algal biotechnology
was Executive Vice President of a multi-billion dollar diversified industrial and financial group based in New York
had a ministerial appointment in the US administration as a principal negotiator in the Tokyo Round of multilateral trade negotiations
is a member of the board of EuropaBio and the executive committee of the British North American Committee
holds an MBA from Harvard University and a BSc from the Georgia Institute of Technology.

Tim Saxon, Business Development

Tim Saxon is based in New Jersey, USA from where he initiates and facilitates the collaboration with leading Pharmaceutical and Biotechnology companies. He

worked for Wyeth at their corporate headquarters in the US from 1999 as Assistant Vice President in Global Business Development
was a consultant for Sagentia, based in Cambridge UK from 1997 until leaving for the US. During this time, Tim served on the Board of Sirus.
worked for British-based Boots Pharmaceuticals and Healthcare International, first in marketing and then in business development between 1991 and 1997.
started his career in the UK, as a chemical engineer in 1978, and then moved into sales and marketing for ICI Pharmaceuticals (now AstraZeneca).
gained his MBA from Loughborough University Business School, England, with distinction.

Jan Jezek, Ph.D, Formulation Development

Jan Jezek is a biochemist with a strong background in physical chemistry and is the principal inventor of the core protein stabilization technology. He

played a key technical role at Insense Ltd in the development of a range of novel active hydrogel wound dressings that are capable of active delivery of oxygen, iodine and nitric oxide to a wound site
held a post-doctoral position at Luton Institute of Research in Applied and Natural Sciences, where he developed successfully novel electrochemical methods for the determination of trace impurities in drinking water
holds a joint doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague.

Helen Young, Ph.D, Director of Development

Helen Young requires a brief bio in the bullet point format as found on the existing website.

bullet one
bullet two
bullet three